江中药业中标贝飞达临床研究项目券商积极评价或提振市场信心

自选股中标信息2025-07-22

2025年07月22日，据天眼查数据，晋城海斯制药有限公司贝飞达干预功能性便秘的临床研究(CRO)的服务商选用单源直接采购结果公告显示，中标方为江中药业（sh600750），招标方为晋城海斯制药有限公司。近半年内，江中药业获得7家券商积极评价：国投证券和开源证券给予"买入"评级。长城证券给予"增持"评级。江中药业主营业务涵盖非处方药（占比约73.63%），处方药（占比约17.88%），健康消费品...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2553232174?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-22 18:07","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2553232174","market":"sh","top_or_hot":-1,"title":"江中药业中标贝飞达临床研究项目 券商积极评价或提振市场信心","media":"自选股中标信息","content":"<div>\n<p>2025年07月22日，据天眼查数据，晋城海斯制药有限公司贝飞达干预功能性便秘的临床研究(CRO)的服务商选用单源直接采购结果公告显示，中标方为江中药业（sh600750），招标方为晋城海斯制药有限公司。近半年内，江中药业获得7家券商积极评价：国投证券和开源证券给予\"买入\"评级。长城证券给予\"增持\"评级。江中药业主营业务涵盖非处方药（占比约73.63%），处方药（占比约17.88%），健康消费品...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722180731a45c1190&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>江中药业中标贝飞达临床研究项目 券商积极评价或提振市场信心</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n江中药业中标贝飞达临床研究项目 券商积极评价或提振市场信心\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-22 18:07 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722180731a45c1190&s=b><strong>自选股中标信息</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>2025年07月22日，据天眼查数据，晋城海斯制药有限公司贝飞达干预功能性便秘的临床研究(CRO)的服务商选用单源直接采购结果公告显示，中标方为江中药业（sh600750），招标方为晋城海斯制药有限公司。近半年内，江中药业获得7家券商积极评价：国投证券和开源证券给予\"买入\"评级。长城证券给予\"增持\"评级。江中药业主营业务涵盖非处方药（占比约73.63%），处方药（占比约17.88%），健康消费品...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722180731a45c1190&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722180731a45c1190&s=b","article_id":"2553232174","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250722180731a45c1190&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2553232174","pubTimestamp":1753178848,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"2025年07月22日，据天眼查数据，晋城海斯制药有限公司贝飞达干预功能性便秘的临床研究的服务商选用单源直接采购结果公告显示，中标方为江中药业，招标方为晋城海斯制药有限公司。近半年内，江中药业获得7家券商积极评价：国投证券和开源证券给予\"买入\"评级。江中药业主营业务涵盖非处方药，处方药，健康消费品及其他，其他收入之和。截至发稿，江中药业股价报22.28元，上涨0.81%，成交额至1.05亿元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"600750":"华润江中","BK0028":"国家队","BK0239":"医药制造","BK0188":"融资融券","BK0175":"白马股"},"translate_title":"Jiangzhong Pharmaceutical won the bid for the Befeida clinical research project, brokers positively evaluated it or boosted market confidence","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600750":1},"content_text":"2025年07月22日，据天眼查数据，晋城海斯制药有限公司贝飞达干预功能性便秘的临床研究(CRO)的服务商选用单源直接采购结果公告显示，中标方为江中药业（sh600750），招标方为晋城海斯制药有限公司。近半年内，江中药业获得7家券商积极评价：国投证券和开源证券给予\"买入\"评级。长城证券给予\"增持\"评级。江中药业主营业务涵盖非处方药（占比约73.63%），处方药（占比约17.88%），健康消费品及其他（占比约7.79%），其他收入之和（占比约0.71%）。截至发稿，江中药业股价报22.28元，上涨0.81%，成交额至1.05亿元（5日均值1.06亿元）。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。中标数据由天眼查提供，由程序或算法识别中标信息页面生成，可能与实际存在差异，不作为决策依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2553232174","isCrawlerRequest":true}

江中药业中标贝飞达临床研究项目 券商积极评价或提振市场信心

精彩评论

江中药业中标贝飞达临床研究项目券商积极评价或提振市场信心